Precision BioSciences, Inc.
DTILPrecision BioSciences is a clinical-stage biotechnology company focused on developing in vivo gene editing therapies using its proprietary ARCUS platform.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Precision BioSciences is a clinical-stage biotechnology company focused on developing in vivo gene editing therapies using its proprietary ARCUS platform. The company leverages a unique synthetic genome editing engine to perform sophisticated genetic modifications including gene insertion, elimination, and excision. Its core value proposition lies in the ARCUS platform's ability to provide highly consistent and predictable therapeutic edits compared to traditional CRISPR-based technologies.
Precision BioSciences positions itself as a specialized alternative to CRISPR, emphasizing the smaller size and higher precision of its ARCUS platform for complex gene insertions and viral DNA elimination.
Questions, answered.
- What is Precision BioSciences, Inc.'s market cap?
- Precision BioSciences, Inc. (DTIL) has a market capitalization of $187.1M and trades on NASDAQ.
- Who are Precision BioSciences, Inc.'s competitors?
- Precision BioSciences, Inc.'s key competitors include Editas Medicine, Inc., Intellia Therapeutics, Inc., CRISPR Therapeutics AG, and others. These companies compete in similar markets and product categories.
- Where is Precision BioSciences, Inc. headquartered?
- Precision BioSciences, Inc. is headquartered in United States of America and employs approximately 109 people. It has been publicly traded since 2019.